Streetbeat News

Analyst Ratings

MVST

Oppenheimer analyst Colin Rusch reiterated an Outperform rating on Microvast Holdings (NASDAQ:MVST) and maintained an $8 price target.

Portfolio Pulse from Benzinga Newsdesk

May 26, 2023 | 3:30 pm

RNG

RingCentral's stock has been volatile since its Q1 results, but the company is making progress towards 20% operating margins. Needham analyst Ryan Koontz upgraded RingCentral from Hold to Buy, with a price target of $42, citing the company's AI strategy and cost-cutting measures.

Portfolio Pulse from Priya Nigam

May 26, 2023 | 3:28 pm

OLED

Oppenheimer analyst Martin Yang reiterates an Outperform rating on Universal Display (NASDAQ:OLED) and maintains a $180 price target.

Portfolio Pulse from Benzinga Newsdesk

May 26, 2023 | 3:25 pm

CNC

Oppenheimer analyst Michael Wiederhorn reiterates an Outperform rating on Centene (NYSE:CNC) and maintains a $110 price target.

Portfolio Pulse from Benzinga Newsdesk

May 26, 2023 | 3:23 pm

ADUS

Oppenheimer analyst Michael Wiederhorn has reiterated an Outperform rating on Addus HomeCare (NASDAQ:ADUS) and maintained a $118 price target.

Portfolio Pulse from Benzinga Newsdesk

May 26, 2023 | 3:19 pm

LEN

A whale has taken a bullish stance on Lennar (NYSE:LEN), with 60% of recent unusual options trades being bullish and 40% bearish. The targeted price range for Lennar over the last 3 months is $106 to $115. Barclays maintains an Overweight rating on Lennar with a price target of $135.

Portfolio Pulse from Benzinga Insights

May 26, 2023 | 3:17 pm

SRPT

Oppenheimer analyst Hartaj Singh has reiterated an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) and maintained a $180 price target.

Portfolio Pulse from Benzinga Newsdesk

May 26, 2023 | 3:16 pm

COST

Costco Wholesale Corporation (NASDAQ:COST) shares recovered slightly after a revenue miss in FQ3. Analysts from Bernstein, Truist Securities, BMO Capital Markets, and Oppenheimer maintained Outperform and Buy ratings, with price targets ranging from $550 to $567. Costco's core shopping drivers remain intact, and the company is expected to emerge from the consumer spending slowdown with a higher market share.

Portfolio Pulse from Priya Nigam

May 26, 2023 | 3:12 pm

PDSB

Oppenheimer analyst Leland Gershell reiterated an Outperform rating on PDS Biotechnology (NASDAQ:PDSB) and maintained a $24 price target.

Portfolio Pulse from Benzinga Newsdesk

May 26, 2023 | 3:12 pm

HRMY

Oppenheimer analyst Francois Brisebois reiterates an Outperform rating on Harmony Biosciences (NASDAQ:HRMY) and maintains a $69 price target.

Portfolio Pulse from Benzinga Newsdesk

May 26, 2023 | 3:10 pm